Company Analysis
Sign in

Eli Lilly & Co. (LLY)

NYSE: LLY · Pharmaceutical Preparations · Indianapolis, IN · filing with the SEC since 1994
Full chart Alerts Compare
Grade7.5
◀ Past 8.1● Present 7.8▶ Future 6.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4,900 patents granted to the 52 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Eli Lilly & Co.’s names, not what it holds today.

Patents granted
4,900
4,766 utility, 88 design, 40 reissue, 6 statutory invention registration, 1976 to Dec 31, 2025
Granted in 2025
106
Against 92 in 2024 and 68 in 2023
Applications published
1,614
142 of them in 2025
Names they are printed under
52
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals153
Organic fine chemistry76
Medical technology74
Biotechnology39
Analysis of biological materials4
Handling2
Other special machines1
Measurement1
Chemical engineering1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name52 counted
Eli Lilly and Company its own name
US, as the owner printed on each patent. 19 more under the same name are not counted (printed in GB, printed in IN)
4,515 granted
369 published
Eli Lilly and Company its own name
named as the applicant on its applications, in US. 3 more under the same name are not counted (printed in IN, printed in GB)
0 granted
762 published
ICOS CORPORATION a subsidiary
US, as the owner printed on each patent
166 granted
59 published
ImClone LLC a subsidiary
US, as the owner printed on each patent
26 granted
22 published
Loxo Oncology, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
43 published
Akouos, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
38 published
Loxo Oncology, Inc. a subsidiary
US, as the owner printed on each patent
34 granted
1 published
SIGILON THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
32 published
Dermira, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
30 published
SGX Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
17 granted
13 published
ARMO BioSciences, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
25 published
Adverum Biotechnologies, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
24 published
Prevail Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
11 granted
11 published
Dermira, Inc. a subsidiary
US, as the owner printed on each patent
15 granted
6 published
Morphic Therapeutic, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
21 published
Verve Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
18 published
Disarm Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Adverum Biotechnologies, Inc. a subsidiary
US, as the owner printed on each patent
11 granted
5 published
Morphic Therapeutic, Inc. a subsidiary
US, as the owner printed on each patent
15 granted
1 published
Prevail Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
16 published
Akouos, Inc. a subsidiary
US, as the owner printed on each patent
14 granted
1 published
ARMO BIOSCIENCES, INC. a subsidiary
US, as the owner printed on each patent
13 granted
1 published
Petra Pharma Corporation a subsidiary
named as the applicant on its applications, in US
0 granted
12 published
COLUCID PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
6 granted
3 published
DISARM THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
8 granted
1 published
Scorpion Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
DICE Molecules SV, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
DiCE Alpha, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
Lilly, SA a subsidiary
ES, as the owner printed on each patent
8 granted
0 published
VERVE THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
8 granted
0 published
Avid Radiopharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
5 published
ICOS CORPORATION a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
POINT BIOPHARMA, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
PROTOMER TECHNOLOGIES, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
SITEONE THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
Avalanche Australia Pty Ltd. a subsidiary
AU, as the owner printed on each patent
2 granted
4 published
ImClone LLC a subsidiary
named as the applicant on its applications, in US
0 granted
6 published
SITEONE THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
6 granted
0 published
DiCE Alpha, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
0 published
PETRA PHARMA CORPORATION a subsidiary
US, as the owner printed on each patent
4 granted
0 published
SIGILON THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
4 granted
0 published
Avalanche Australia Pty Ltd. a subsidiary
named as the applicant on its applications, in AU
0 granted
3 published
COLUCID PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
MABLINK BIOSCIENCE a subsidiary
named as the applicant on its applications, in FR
0 granted
3 published
PROTOMER TECHNOLOGIES, INC. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
Scorpion Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
DiCE Molecules SV, LLC a subsidiary
US, as the owner printed on each patent
1 granted
1 published
Lilly Korea, Ltd. a subsidiary
KR, as the owner printed on each patent
1 granted
1 published
MABLINK BIOSCIENCE a subsidiary
FR, as the owner printed on each patent
0 granted
2 published
POINT Biopharma, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Versanis Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Eli Lilly Japan Kabushiki Kaisha a subsidiary
JP, as the owner printed on each patent
1 granted
0 published
Names not counted (5)
ELI LILLY & Co
No country is printed for it. 0 granted and 4 published under it are not counted.
Lilly S.A.
Most of its patents print US; this name counts in ES. 4 granted and 0 published under it are not counted.
Victoria Holdco Corp.
Most of its patents print NL; this name counts in US. 0 granted and 2 published under it are not counted.
Victoria Holdco Corp.
Most of its patents print NL; this name counts in US. 0 granted and 2 published under it are not counted.
Dista, S.A.
Most of its patents print US; this name counts in ES. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,377Nasal delivery device with trigger and spring-loaded activatorMedical technologyEli Lilly and Company
Dec 23, 2025D1,107,216TabletEli Lilly and Company
Dec 23, 202512,505,906Methods and apparatus for determining device dosageMedical technologyEli Lilly and Company
Dec 23, 202512,503,442Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulatorsPharmaceuticalsEli Lilly and Company
Dec 23, 202512,502,380MrgprX2 antagonists for the treatment of inflammatory disordersPharmaceuticalsDermira, Inc.
Dec 16, 202512,496,329Methods of using and compositions including an incretin analogPharmaceuticalsEli Lilly and Company
Dec 9, 202512,491,223Method for treating an auditory neuropathy spectrum disorderPharmaceuticalsAkouos, Inc.
Dec 9, 202512,491,160Formulations of a farnesoid X receptor agonistPharmaceuticalsEli Lilly and Company
Dec 2, 202512,486,249SSTR4 agonist saltsPharmaceuticalsEli Lilly and Company
Dec 2, 202512,485,402Three resin reactors in series peptide synthesizerBiotechnologyEli Lilly and Company
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387602ORAL DRUG DELIVERY DEVICE WITH EXPANDING ARMSMedical technologyEli Lilly and Company
Dec 18, 20252025/0382615NOVEL RNA THERAPEUTICS AND USES THEREOFBiotechnologyEli Lilly and Company
Dec 18, 20252025/0382345PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONISTBiotechnologyEli Lilly and Company
Dec 18, 20252025/0382271SODIUM-HYDROGEN EXCHANGER 3 INHIBITOR COMPOUNDSPharmaceuticalsEli Lilly and Company
Dec 18, 20252025/0381284PRNP RNAi AGENTSPharmaceuticalsEli Lilly and Company
Dec 18, 20252025/0381199PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULINPharmaceuticalsEli Lilly and Company
Dec 4, 20252025/0367253GIP/GLP1 AGONIST COMPOSITIONSPharmaceuticalsEli Lilly and Company
Nov 27, 20252025/0360227MELANOPSIN VARIANTS FOR VISION RESTORATIONPharmaceuticalsAdverum Biotechnologies, Inc.
Nov 20, 20252025/0353874GLUCOCORTICOID RECEPTOR AGONISTSPharmaceuticalsEli Lilly and Company
Nov 20, 20252025/0352734MEDICATION DELIVERY DEVICE INCLUDING DISPOSABLE AND REUSABLE PORTIONSMedical technologyEli Lilly and Company
What it applied for, 2024 to 2025: Pharmaceuticals 159 · Biotechnology 50 · Organic fine chemistry 45 · Medical technology 44 · Analysis of biological materials 5 · Computer technology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LLY · research, not advice